Amicogen

아미코젠 · 092040

Consumer Staples Food & Beverage · KOSDAQ

Small-cap

Market cap US$76M (₩104.9B)

Overview

Amicogen makes specialist enzymes used in producing antibiotic ingredients, for example, the enzyme needed to manufacture the raw material at the heart of cephalosporin-class antibiotics, and has expanded into health-care ingredients such as collagen peptides and N-acetylglucosamine, as well as materials used in making antibody-based medicines.

Its customers include pharmaceutical manufacturers and biotech producers that rely on these inputs. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business spans three areas: pharmaceutical enzymes, consumer health ingredients marketed under its own brand, and biopharmaceutical production materials.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$30.4M
▼ −75.8% YoY
Operating profit · FY2025
−US$12.4M
Loss widened
Net income · FY2025
−US$22M
Loss narrowed

Revenue

  • FY2023US$115.9M
  • FY2024US$125.8M
  • FY2025US$30.4M

Operating profit

  • FY2023US$1.5M
  • FY2024−US$5.1M
  • FY2025−US$12.4M

Net income

  • FY2023−US$15M
  • FY2024−US$36.9M
  • FY2025−US$22M

Key ratios (FY2025)

ROE
-31.7%
Debt/Eq
141.9%
Op. margin
-40.8%
Net margin
-72.3%
Rev. YoY
▼ −75.8%

Why it matters

Amicogen collaborates with Liechtenstein-based Lysando on commercialising endolysin enzymes, a next-generation antibiotic class targeting drug-resistant bacteria.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.